Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor

[1]  E. Klein,et al.  Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. , 2010, Urologic oncology.

[2]  P. Albers,et al.  Retroperitoneal lymph node dissection after chemotherapy , 2009, BJU international.

[3]  J. Eastham.  Do high-volume hospitals and surgeons provide better care in urologic oncology? , 2009, Urologic oncology.

[4]  M. Shields,et al.  Factors related to on-the-job abuse of nurses by patients. , 2009, Health reports.

[5]  K. Wilkins,et al.  Cancer prevalence in the Canadian population. , 2009, Health reports.

[6]  J. Richie,et al.  Retroperitoneal lymph node dissection in patients with high risk testicular cancer. , 2008, The Journal of urology.

[7]  J. Richie.  Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? , 2008 .

[8]  L. Einhorn,et al.  Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? , 2007, Cancer.

[9]  W. Siegert,et al.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[11]  J. Habbema,et al.  External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients , 2003, British Journal of Cancer.

[12]  L. Kiemeney,et al.  The role of 18fluoro‐2‐deoxyglucose positron emission tomography in initial staging and re‐staging after chemotherapy for testicular germ cell tumours , 2002, BJU international.

[13]  D. Dearnaley,et al.  Metastatic nonseminomatous germ cell tumors of the testis , 2002, Cancer.

[14]  J. Donohue,et al.  Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. , 2001, The Journal of urology.

[15]  S. Fosså,et al.  Postchemotherapy residual masses in germ cell tumor patients , 1998, Cancer.

[16]  J. Donohue,et al.  Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy? , 1998, The Urologic clinics of North America.

[17]  J. Sheinfeld,et al.  Role of surgery in management of germ cell tumor. , 1998, Seminars in oncology.

[18]  C. Bokemeyer,et al.  Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. , 1997, European journal of cancer.

[19]  J. Donohue,et al.  Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. , 1996, The Journal of urology.

[20]  I. Leibovitch,et al.  Hyperamylasemia after post-chemotherapy retroperitoneal lymph node dissection for testis cancer. , 1995, The Journal of urology.

[21]  J. Baniel,et al.  Complications of post-chemotherapy retroperitoneal lymph node dissection. , 1995, The Journal of urology.

[22]  J. Baniel,et al.  Original Articles: Testis Cancer: Complications of Post-Chemotherapy Retroperitoneal Lymph Node Dissection , 1995 .

[23]  D. Bajorin,et al.  Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors , 1994, Cancer.